Compare HCKT & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCKT | NBP |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | 32 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 379.3M |
| IPO Year | 1998 | N/A |
| Metric | HCKT | NBP |
|---|---|---|
| Price | $13.08 | $2.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $17.00 | $9.00 |
| AVG Volume (30 Days) | 217.4K | ★ 873.2K |
| Earning Date | 05-05-2026 | 04-07-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $285,862,000.00 | N/A |
| Revenue This Year | $2.55 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $28.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.19 | $2.10 |
| 52 Week High | $26.74 | $5.19 |
| Indicator | HCKT | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 38.72 |
| Support Level | $12.42 | $2.27 |
| Resistance Level | $14.67 | $2.78 |
| Average True Range (ATR) | 0.52 | 0.13 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 34.88 | 26.47 |
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.